Khloé Kardashian, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Khloé Kardashian, Maintenance, and What Happens If You Stop

The Public Record: What Khloé Has Actually Said

Between 2022 and 2024, Khloé Kardashian's visible physical transformation became a consistent tabloid subject. In multiple interviews and social media posts, she credited her results to disciplined gym routines, dietary changes, and the emotional aftermath of personal upheaval. On a 2023 episode of The Kardashians on Hulu, she discussed her workout regimen in detail, framing fitness as a coping mechanism rather than a cosmetic project.

She has never publicly confirmed taking semaglutide, tirzepatide, or any other GLP-1 receptor agonist.

Her family, by contrast, has been more open. Kim Kardashian acknowledged using semaglutide to lose weight before the 2022 Met Gala, though she later clarified she stopped taking it. The broader Kardashian-Jenner family's visibility around weight management has made every member a subject of GLP-1 speculation, whether warranted or not.

The HealthRX Medical Team wants to be direct: attributing GLP-1 use to Khloé Kardashian without her confirmation is speculation. This page does not assert she has used these medications. What this page does is address the clinical questions her public story surfaces, because those questions are real for the millions of women in her demographic who are considering or currently taking GLP-1 agonists.

At a glance

  • Confirmed GLP-1 use by Khloé Kardashian? No. She has publicly attributed her weight loss to exercise and lifestyle.
  • Family connection to GLP-1s? Yes. Kim Kardashian publicly confirmed short-term semaglutide use in 2022.
  • Why this page exists: Public speculation around Khloé's body composition raises legitimate clinical questions about GLP-1 discontinuation and weight maintenance that affect a large patient population.
  • Key clinical finding: The STEP 1 extension trial showed participants regained roughly two-thirds of lost weight within one year of stopping semaglutide.
  • Bottom line from the HealthRX Medical Team: Stopping a GLP-1 without a structured maintenance plan carries a high probability of weight regain. The drug is not a temporary fix for most patients.

What the Clinical Literature Says About Stopping a GLP-1

The question "what happens when you stop?" is not hypothetical. It is one of the most studied aspects of the GLP-1 drug class, and the data is consistent.

The STEP 1 Extension Trial

The landmark STEP 1 trial extension published in Diabetes, Obesity and Metabolism (2022) followed participants who had lost an average of 17.3% of body weight on semaglutide 2.4 mg over 68 weeks. After discontinuation, participants regained approximately two-thirds of that weight within 52 weeks. Cardiometabolic improvements in blood pressure, lipid profiles, and HbA1c also reversed in parallel.

This was not a surprise to endocrinologists. Obesity is classified as a chronic, relapsing condition by the Endocrine Society, and the neurohormonal pathways GLP-1 agonists modulate (appetite signaling via hypothalamic GLP-1 receptors, delayed gastric emptying, insulin sensitization) revert to baseline once the drug clears the system.

The SURMOUNT-4 Tirzepatide Data

The SURMOUNT-4 trial published in JAMA (2023) reinforced these findings with tirzepatide. Patients who switched from tirzepatide to placebo after 36 weeks of treatment regained roughly half of their lost weight over the following 52 weeks. Those who continued tirzepatide lost an additional 5.5% of body weight during the same period.

The gap between the two groups widened every month. By week 88, the difference in body weight between continuers and discontinuers was approximately 14 percentage points.

Why Rebound Happens: The Biology

GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which signals satiety to the brain, slows gastric emptying, and enhances glucose-dependent insulin secretion. When the drug is withdrawn, these effects disappear within days to weeks (the half-life of semaglutide is approximately 7 days; tirzepatide, approximately 5 days).

The body's weight-defense system then reasserts itself. Levels of the hunger hormone ghrelin rise. Leptin levels, which had dropped with weight loss, signal the hypothalamus that energy stores are depleted. Resting metabolic rate may remain suppressed from the prior weight loss, creating a caloric environment that favors regain. This is the same metabolic adaptation documented in non-pharmacological weight loss, compounded by the loss of appetite suppression the drug was providing.

What "Maintenance" Actually Looks Like on a GLP-1

For patients who remain on therapy, the clinical picture is more encouraging. The STEP 5 trial followed semaglutide patients for two full years and found that weight loss was sustained at approximately 15% below baseline, with continued cardiometabolic benefit, as long as dosing continued.

The practical question becomes whether indefinite use is safe, affordable, and tolerable.

Long-Term Safety Signals

The SELECT cardiovascular outcomes trial (published in NEJM, 2023) followed over 17,600 patients on semaglutide 2.4 mg for a mean of 39.8 months. The drug reduced major adverse cardiovascular events by 20% compared to placebo. Serious adverse events were comparable between groups, though gastrointestinal side effects (nausea, vomiting, diarrhea) remained the most common reason for discontinuation.

Longer-term safety data beyond 3 to 4 years is still limited. The FDA's prescribing information for semaglutide carries a boxed warning regarding medullary thyroid carcinoma risk based on rodent studies, though this has not been observed in human clinical trials to date.

The Cost Problem

A year of branded semaglutide (Wegovy) carries a list price exceeding $15,000 annually. Tirzepatide (Zepbound) is comparably priced. Insurance coverage varies widely and is often denied for patients who do not meet specific BMI or comorbidity thresholds. For patients who lose coverage or cannot sustain out-of-pocket costs, discontinuation is not a clinical choice. It is a financial one.

This financial dimension is relevant to the Kardashian conversation. Celebrities with unlimited resources face a fundamentally different maintenance calculus than a 34-year-old woman paying $1,300 per month out of pocket.

The HealthRX Medical Team Take

The clinical evidence is clear on three points.

First, GLP-1 receptor agonists are not short-course medications for most patients. The STEP 1 extension and SURMOUNT-4 data show that stopping therapy results in significant weight regain for the majority of participants. Anyone beginning a GLP-1 should understand this before the first injection.

Second, long-term continuation appears safe based on the data available through 3 to 4 years, and the cardiovascular benefit observed in SELECT adds a meaningful argument for sustained use in patients with established cardiovascular risk.

Third, lifestyle interventions (resistance training, protein-adequate nutrition, behavioral counseling) during GLP-1 therapy may improve outcomes after discontinuation, though no trial has yet demonstrated a protocol that fully prevents rebound. A 2024 review in The Lancet Diabetes & Endocrinology emphasized that combining pharmacotherapy with structured exercise preserved more lean mass and may attenuate regain, though the evidence base remains early.

Khloé Kardashian's public emphasis on exercise is, from a clinical standpoint, the right message regardless of whether she uses a GLP-1. Resistance training during weight loss, pharmacological or otherwise, is the single best-studied intervention for preserving muscle mass and supporting resting metabolic rate.

What the HealthRX Medical Team would tell any patient in this position: if you are on a GLP-1 and considering stopping, do so with medical supervision, taper expectations, and have a concrete maintenance plan. If you are not on one and are achieving results through lifestyle alone, the durability of those results depends on whether the habits are sustainable, not on whether they produce dramatic short-term change.

Frequently asked questions

›
›
›
›
›

References